OPKO Health - OPK Stock Forecast, Price & News

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler cut their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Friday.

OPKO Health Stock Performance

OPKO Health stock opened at $2.45 on Tuesday. The company has a market capitalization of $1.67 billion, a PE ratio of -8.45 and a beta of 1.75. The firm has a fifty day simple moving average of $2.60 and a two-hundred day simple moving average of $2.97. The company has a quick ratio of 1.91, a current ratio of 2.30 and a debt-to-equity ratio of 0.12. OPKO Health has a twelve month low of $2.15 and a twelve month high of $5.25.

OPKO Health (NASDAQ:OPK - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.12). The firm had revenue of $309.90 million for the quarter, compared to analysts' expectations of $326.87 million. OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.72%. The company's quarterly revenue was down 30.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. Research analysts expect that OPKO Health will post -0.22 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 350,000 shares of the business's stock in a transaction that occurred on Friday, August 5th. The stock was bought at an average cost of $2.29 per share, with a total value of $801,500.00. Following the completion of the purchase, the chief executive officer now owns 196,956,694 shares of the company's stock, valued at approximately $451,030,829.26. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 350,000 shares of the company's stock in a transaction on Friday, August 5th. The stock was acquired at an average cost of $2.29 per share, with a total value of $801,500.00. Following the purchase, the chief executive officer now directly owns 196,956,694 shares of the company's stock, valued at approximately $451,030,829.26. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Gary J. Nabel bought 240,000 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was purchased at an average price of $2.49 per share, with a total value of $597,600.00. Following the acquisition, the insider now directly owns 19,857,514 shares in the company, valued at approximately $49,445,209.86. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,590,000 shares of company stock worth $4,114,100. Company insiders own 40.97% of the company's stock.